FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

Immunomodulatory monoclonal IgG1 antibodies developed for cancer and autoimmune disease have an inherent risk of systemic release of pro-inflammatory cytokines. In vitro cytokine release assays are currently used to predict cytokine release syndrome (CRS) risk, but the validation of these preclinica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Alakhras, Nada S., Qiu, Jiabin, Rocha, Guilherme V., Witcher, Derrick R., Koester, Anja, You, Jinsam, Schaer, David A., Holmgaard, Rikke B., Driscoll, Kyla, Willy, Jeffrey A., Malherbe, Laurent P.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152447/
https://ncbi.nlm.nih.gov/pubmed/29953319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1474996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados